MYC and cancer: Among the aforementioned studies, several involved ISR signaling in drug‐mediated killing of cancer cells [306] and this was verified with OxPhos inhibitors, including IACS‐010759 in MYC‐overexpressing lymphoma [292] and MM [297], as well as Tigecycline in FBXW7‐knockout cells [305].